Ayala Pharmaceuticals Inc (ADXS)

[ignatiusrielly35]

The issue has never been out to Congress. And there is no way that even the clueless SEC would arrive at the following conclusion: we want to make it cheaper for biotechs to acquire companies by permitting them to withhold material information from the market and the target’s own shareholders. The examples that your article cites are nothing more than anomalies. There is no general rule permitting such non-disclosure of material facts and the accumulation of shares beyond certain key thresholds. This scenario of a secret accumulation of ADXS by Amgen remains a major long shot at best.